Compositions for topical delivery of prostaglandins to subcutaneous fat
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-031/557
A61K-047/14
A61K-031/5575
A61K-047/06
A61K-009/00
출원번호
US-0575873
(2014-12-18)
등록번호
US-9040584
(2015-05-26)
발명자
/ 주소
Singer, Michael S.
Kalayoglu, Murat V.
출원인 / 주소
Topokine Therapeutics, Inc.
대리인 / 주소
Wolf, Greenfield & Sacks, P.C.
인용정보
피인용 횟수 :
11인용 특허 :
59
초록▼
Described herein are compositions comprising a prostaglandin FP receptor agonist (PFPRA) compound and a fatty acid ester (e.g., isopropyl myristate), optionally comprising an ointment base such as a hydrocarbon base (e.g., petroleum jelly) and/or an organic alcohol (e.g., propylene glycol), that, wh
Described herein are compositions comprising a prostaglandin FP receptor agonist (PFPRA) compound and a fatty acid ester (e.g., isopropyl myristate), optionally comprising an ointment base such as a hydrocarbon base (e.g., petroleum jelly) and/or an organic alcohol (e.g., propylene glycol), that, when topically applied to the skin, locally delivers a therapeutically effective amount of the PFPRA compound to subcutaneous fat under the skin, and methods of preparation. The therapeutic effect is, for example, reduction of the subcutaneous fat under the skin. Further provided are methods of reducing body fat in a subject comprising topically administering the composition to the subject.
대표청구항▼
1. A composition comprising latanoprost, isopropyl myristate, and petroleum jelly. 2. The composition of claim 1, consisting essentially of latanoprost, isopropyl myristate, and petroleum jelly. 3. The composition of claim 1, wherein the latanoprost concentration is between about 0.01% and about 0.5
1. A composition comprising latanoprost, isopropyl myristate, and petroleum jelly. 2. The composition of claim 1, consisting essentially of latanoprost, isopropyl myristate, and petroleum jelly. 3. The composition of claim 1, wherein the latanoprost concentration is between about 0.01% and about 0.5% w/w. 4. The composition of claim 3, wherein the latanoprost concentration is between about 0.03% and about 0.1% w/w. 5. The composition of claim 2, wherein the latanoprost concentration is between about 0.01% and about 0.5% w/w. 6. The composition of claim 5, wherein the latanoprost concentration is between about 0.03% and about 0.1% w/w. 7. The composition of claim 1, wherein the isopropyl myristate concentration is between about 1% and about 20% w/w. 8. The composition of claim 7 wherein the isopropyl myristate concentration is between about 1% and about 10% w/w. 9. The composition of claim 7 wherein the isopropyl myristate concentration is between about 5% and about 15% w/w. 10. The composition of claim 2, wherein the isopropyl myristate concentration is between about 1% and about 20% w/w. 11. The composition of claim 10, wherein the isopropyl myristate concentration is between about 1% and about 10% w/w. 12. The composition of claim 10, wherein the isopropyl myristate concentration is between about 5% and about 15% w/w. 13. The composition of claim 1, wherein the petroleum jelly concentration is between about 70% and about 99% w/w. 14. The composition of claim 2, wherein the petroleum jelly concentration is between about 70% and about 99% w/w. 15. The composition of claim 1, further comprising a preservative. 16. The composition of claim 2, further comprising a preservative. 17. The composition of claim 1, wherein the composition is sterile. 18. The composition of claim 2, wherein the composition is sterile. 19. The composition of claim 1, wherein the latanoprost concentration is between about 0.01% and 0.5% w/w; the isopropyl myristate concentration is between about 1% and about 10% w/w; and the petroleum jelly concentration is between about 70% and about 99% w/w. 20. The composition of claim 2, wherein the latanoprost concentration is between about 0.01% and 0.5% w/w; the isopropyl myristate concentration is between about 1% and about 10% w/w; and the petroleum jelly concentration is between about 70% and about 99% w/w.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (59)
Feng Zixia ; Hellberg Mark R., 13-Oxa prostaglandins for the treatment of glaucoma and ocular hypertension.
Ling, Kah-Hiing John; Yang, Wu; Ni, Jinsong; Yuan, Haiqing; Tang-Liu, Diane D. S., 9,11-cycloendoperoxide pro-drugs of prostaglandin analogues for treatment of ocular hypertension and glaucoma.
Hubbard Vance M. (Bedford) Brunson Welton K. (Bedford) Saied V. C. (Wichita Falls TX), Apparatus and method for raising a skin wheal and anesthetizing skin.
Woodward David F. (El Toro CA) Andrews Steven W. (Rancho Santa Marguerita CA) Burk Robert M. (Irvine CA) Garst Michael E. (Newport Beach CA), Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents.
Lilley Stephen J. (Sawston GBX) Taylor Hugh F. (Sawston GBX) Theobald David R. (Huntingdon GBX) Carlson Craig J. (Andover MA) Rosen David I. (Arlington MA) Johnson Thomas R. (Milford NH), Medical injection system and method, gas spring thereof and launching device using gas spring.
Tennenbaum, Tamar; Braiman-Wiksman, Liora; Solominik, Inessa; Meir, Michal, Method and compositions for prevention and treatment of diabetic and aged skin.
Pintor, Jesus J.; Peral, Maria A.; Peterson, Ward M.; Plourde, Jr., Robert; Brown, Edward G.; Yerxa, Benjamin R., Method for reducing intraocular pressure using indole derivatives.
McKinnon ; Jr. Charles N. (Laguna Niguel CA) Peterson Steven F. (West Linn OR) Smith Paul E. (Tualatin OR) Nakagawa Takaaki (Tigard OR) Bartholomew Victor L. (Tigard OR), Needleless hypodermic injection device.
Peterson Steven F. (West Linn OR) McKinnon ; Jr. Charles N. (Laguna Niguel CA) Smith Paul E. (Tualatin OR) Nakagawa Takaaki (Tigard OR) Bartholomew Victor L. (Tigard OR), Needleless hypodermic injection methods and device.
David F. Woodward ; Steven W. Andrews ; Robert M. Burk ; Michael E. Garst, Non-acidic cyclopentane heptanoic acid,2-cycloalkyl or arylalkyl derivatives as therapeutic agents.
Klimko Peter G. ; Bishop John E. ; Sallee Verney L. ; Zinke Paul W., Use of cloprostenol and fluprostenol analogues to treat glaucoma and ocular hypertension.
Hellberg, Mark R.; Nixon, Jon C., Use of non-steroidal anti-inflammatory agents in combination with prostaglandin FP receptor agonists to treat glaucoma and ocular hypertension.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.